# Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy

> **NCT02863354** · PHASE2 · COMPLETED · sponsor: **Charles C Wykoff, PhD, MD** · enrollment: 43 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02863354
- **Lead sponsor:** Charles C Wykoff, PhD, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02863354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02863354, "Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02863354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*